Literature DB >> 18826333

Reconstructed epidermis and full-thickness skin for absorption testing: influence of the vehicles used on steroid permeation.

Monika Schäfer-Korting1, Ashraf Mahmoud, Simone Lombardi Borgia, Barbara Brüggener, Burkhard Kleuser, Sylvia Schreiber, Wolfgang Mehnert.   

Abstract

A protocol for percutaneous absorption studies has been validated, based on the use of reconstructed human epidermis (RHE) and aqueous solutions of test substances. However, it is often the case that it is more-complex formulations of drugs or chemicals which will make contact with the skin surface. To investigate whether RHE and the reconstructed full-thickness skin model (FT-model) can be used to predict uptake from formulations, we compared the permeation of hydrocortisone and testosterone when applied in emulsion form and as a solution containing the penetration enhancer, ethanol. Human and pig skin and a non-cornified alveolar model served as references. The results were compared with steroid release from the formulations. The permeation rates of the steroids were ranked as: alveolar model >> RHE > FT-model, pig skin > human skin. In accordance with the rapid hydrocortisone release from the formulations, the permeation rates of this steroid exceeded those of testosterone. Only minor differences were observed when comparing the testosterone formulations, in terms of release and permeation. However, the ranking of the permeation of the hydrocortisone formulations was: solution > w/o emulsion > o/w emulsion, which permitted the elucidation of penetration enhancing effects, which is not possible with drug release studies. Differences in penetration were most obvious with native skin and reconstructed tissues, which exhibited a well-developed penetration barrier. In conclusion, RHE and skin preparations may be useful in the development of topical dermatics, and in the framework of hazard analysis of toxic compounds and their various formulations. 2008 FRAME.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826333     DOI: 10.1177/026119290803600405

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  5 in total

1.  In Vitro Modeling of Skin Barrier Disruption and its Recovery by Ceramide-Based Formulations.

Authors:  Barbora Amélie Čuříková-Kindlová; Aneta Vovesná; Anna Nováčková; Jarmila Zbytovská
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

2.  In-Vivo Tape Stripping Study with Caffeine for Comparisons on Body Sites, Age and Washing.

Authors:  William Wargniez; Sophie Connétable; Nasrine Bourokba; Olivia Dufour; Stéphanie Nouveau; Sébastien Grégoire
Journal:  Pharm Res       Date:  2022-06-21       Impact factor: 4.580

Review 3.  State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology.

Authors:  Natalie Alépée; Anthony Bahinski; Mardas Daneshian; Bart De Wever; Ellen Fritsche; Alan Goldberg; Jan Hansmann; Thomas Hartung; John Haycock; Helena Hogberg; Lisa Hoelting; Jens M Kelm; Suzanne Kadereit; Emily McVey; Robert Landsiedel; Marcel Leist; Marc Lübberstedt; Fozia Noor; Christian Pellevoisin; Dirk Petersohn; Uwe Pfannenbecker; Kerstin Reisinger; Tzutzuy Ramirez; Barbara Rothen-Rutishauser; Monika Schäfer-Korting; Katrin Zeilinger; Marie-Gabriele Zurich
Journal:  ALTEX       Date:  2014-07-14       Impact factor: 6.043

4.  Alternatives to animal testing: current status and future perspectives.

Authors:  Manfred Liebsch; Barbara Grune; Andrea Seiler; Daniel Butzke; Michael Oelgeschläger; Ralph Pirow; Sarah Adler; Christian Riebeling; Andreas Luch
Journal:  Arch Toxicol       Date:  2011-08       Impact factor: 5.153

5.  Comet assay in reconstructed 3D human epidermal skin models--investigation of intra- and inter-laboratory reproducibility with coded chemicals.

Authors:  Astrid A Reus; Kerstin Reisinger; Thomas R Downs; Gregory J Carr; Andreas Zeller; Raffaella Corvi; Cyrille A M Krul; Stefan Pfuhler
Journal:  Mutagenesis       Date:  2013-11       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.